Rhenium-188 HEDP dose escalation
Palmedo and colleagues gave escalating doses of rhenium-188 HEDP to 22 prostate cancer patients with painful bone metastases; 64% reported pain relief, and low platelet and white-cell counts were the main side effects.
As reported in: Palmedo, Guhlke, Bender et al. (2000). Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. European Journal of Nuclear Medicine and Molecular Imaging. doi:10.1007/s002590050017
Abstract only